Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 60 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $152.455 thousand which missed the analyst consensus estimate of $984.667 thousand by 84.52 percent. This is a 499.58 percent increase over sales of $25.427 thousand the same period last year.